David Geldmacher

14.6k total citations · 1 hit paper
100 papers, 4.7k citations indexed

About

David Geldmacher is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Physiology. According to data from OpenAlex, David Geldmacher has authored 100 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Psychiatry and Mental health, 20 papers in Cognitive Neuroscience and 20 papers in Physiology. Recurrent topics in David Geldmacher's work include Dementia and Cognitive Impairment Research (45 papers), Alzheimer's disease research and treatments (17 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). David Geldmacher is often cited by papers focused on Dementia and Cognitive Impairment Research (45 papers), Alzheimer's disease research and treatments (17 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). David Geldmacher collaborates with scholars based in United States, Australia and Canada. David Geldmacher's co-authors include Karl Herrup, Yanxu Yang, Peter J. Whitehouse, Richard C. Mohs, Steven H. Ferris, Michael Grundman, Mary Sano, Linas A. Bieliauskas, Milton E. Strauss and Susan D. Sperry and has published in prestigious journals such as New England Journal of Medicine, Journal of Neuroscience and Neurology.

In The Last Decade

David Geldmacher

94 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DNA Replication Precedes Neuronal Cell Death in Alzheimer's Disease

2001 506 citations David Geldmacher et al. profile →

Peers

David Geldmacher

PMH

PHYSI

NEURO

J. Wesson Ashford United States

Alireza Atri United States

Andrew Satlin United States

Lutz Froelich Germany

Richard Harvey United Kingdom

María M. Corrada United States

Seol‐Heui Han South Korea

Bengt Winblad Sweden

Jeremy M. Silverman United States

Po H. Lu United States

J. Wesson Ashford United States

David Geldmacher

2.0k ×1.1

PMH

2.0k ×1.4

PHYSI

868 ×1.0

665 ×0.8

515 ×0.8

NEURO

Citations per year, relative to David Geldmacher David Geldmacher (= 1×) peers J. Wesson Ashford

Countries citing papers authored by David Geldmacher

Since Specialization

Citations

This map shows the geographic impact of David Geldmacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Geldmacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Geldmacher more than expected).

Fields of papers citing papers by David Geldmacher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Geldmacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Geldmacher. The network helps show where David Geldmacher may publish in the future.

Co-authorship network of co-authors of David Geldmacher

This figure shows the co-authorship network connecting the top 25 collaborators of David Geldmacher. A scholar is included among the top collaborators of David Geldmacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Geldmacher. David Geldmacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Puga, Frank, et al.. (2023). PATIENT PORTAL USE IN FAMILY CAREGIVERS OF PATIENTS WITH DEMENTIA OR CANCER: THE NATIONAL STUDY OF CAREGIVING. Innovation in Aging. 7(Supplement_1). 1094–1095.

Cochran, J. Nicholas, James M.J. Lawlor, Michelle D. Amaral, et al.. (2023). Contributions of rare and common variation to early-onset and atypical dementia risk. Molecular Case Studies. 9(3). a006271–a006271.

Merritt, Stacy, David A. Raichlen, Georg A. Hishaw, et al.. (2022). Validity of the NIH toolbox cognitive battery in a healthy oldest-old 85+ sample. Journal of the International Neuropsychological Society. 29(6). 605–614. 7 indexed citations

McKinley, Emily, J. Nicholas Cochran, Michelle D. Amaral, et al.. (2019). Genome sequencing for early-onset or atypical dementia: high diagnostic yield and frequent observation of multiple contributory alleles. Molecular Case Studies. 5(6). a003491–a003491. 22 indexed citations

Geldmacher, David, Noam Y. Kirson, Howard G. Birnbaum, et al.. (2013). Pre-Diagnosis Excess Acute Care Costs in Alzheimer’s Patients among a US Medicaid Population. Applied Health Economics and Health Policy. 11(4). 407–413. 28 indexed citations

Cummings, Jeffrey L., David Geldmacher, Martin R. Farlow, et al.. (2013). High‐Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines. CNS Neuroscience & Therapeutics. 19(5). 294–301. 50 indexed citations

Geldmacher, David, Bonnie Levin, & Clinton B. Wright. (2012). Characterizing healthy samples for studies of human cognitive aging. Frontiers in Aging Neuroscience. 4. 23–23. 7 indexed citations

Doody, Rachelle S., David Geldmacher, Martin R. Farlow, et al.. (2012). Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer’s Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine. Dementia and Geriatric Cognitive Disorders. 33(2-3). 164–173. 33 indexed citations

Geldmacher, David, et al.. (2011). Family quality of life in dementia: a qualitative approach to family-identified care priorities. Quality of Life Research. 20(8). 1331–1335. 11 indexed citations

10.

Geldmacher, David, Thomas Fritsch, McKee J. McClendon, & Gary E. Landreth. (2010). A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease. Archives of Neurology. 68(1). 45–50. 178 indexed citations

11.

Geldmacher, David, et al.. (2004). Interdisciplinary approaches to Alzheimer's disease management. Clinics in Geriatric Medicine. 20(1). 121–139. 19 indexed citations

12.

Geldmacher, David, George Provenzano, Thomas McRae, Vera Mastey, & John R. Ieni. (2003). Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease. Journal of the American Geriatrics Society. 51(7). 937–944. 216 indexed citations

13.

Fillit, Howard, et al.. (2002). Optimizing Coding and Reimbursement to Improve Management of Alzheimer's Disease and Related Dementias. Journal of the American Geriatrics Society. 50(11). 1871–1878. 82 indexed citations

14.

Geldmacher, David. (2002). Cost-Effective Recognition and Diagnosis of Dementia. Seminars in Neurology. 22(1). 63–70. 21 indexed citations

15.

Hills, Everett C. & David Geldmacher. (1998). The effect of character and array type on visual spatial search quality following traumatic brain injury. Brain Injury. 12(1). 69–76. 29 indexed citations

16.

Mohs, Richard C., David S. Knopman, Ronald C. Petersen, et al.. (1997). Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs. Alzheimer Disease & Associated Disorders. 11. 13–21. 495 indexed citations

17.

Gauthier, Serge, N. Bodick, Howard Feldman, et al.. (1997). Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.. PubMed. 11 Suppl 3. 6–7. 22 indexed citations

18.

Brodaty, Henry, Serge Gauthier, David Geldmacher, et al.. (1997). Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.. UCL Discovery (University College London). 11 Suppl 3. 26–8. 2 indexed citations

19.

Whitehouse, Peter J., Marian B. Patterson, Milton E. Strauss, et al.. (1997). Hallucinations. International Psychogeriatrics. 8. 387–392. 2 indexed citations

20.

Geldmacher, David. (1996). Effects of Stimulus Number and Target-to-Distractor Ratio on the Performance of Random Array Letter Cancellation Tasks. Brain and Cognition. 32(3). 405–415. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact